Infliximab in the treatment of Budd-Chiari syndrome in Behçet’s disease

  • L.B. Santos | santos.lilianaribeiro@gmail.com Service of Internal Medicine 2B, Hospital of Santa Maria/Centro Hospitalar Lisboa Norte, Portugal.
  • J. Rigueira Service of Internal Medicine 2B, Hospital of Santa Maria/Centro Hospitalar Lisboa Norte, Portugal.
  • A.P. Vilas Service of Internal Medicine 2B, Hospital of Santa Maria/Centro Hospitalar Lisboa Norte, Portugal.

Abstract

Behçet’s disease is a chronic autoinflammatory disorder that usually presents with recurrent oral and genital ulcers, uveitis, skin lesions and arthritis. Any organ, however, can be involved and in a subgroup of patients the large vascular lesions are the predominant feature (vasculo-Behçet disease). We report a case of a 27-yearold man with Behçet’s disease who developed Budd-Chiari syndrome while on immunosuppressive therapy. Infliximab resulted in a rapid and total clinical remission. Literature data have shown that antitumor necrosis factor alpha (anti-TNF-α) agents including infliximab can suppress disease activity but there is no long-term experience on tapering and/or discontinuation of treatment under clinical remission. Our case supports the use of infliximab in vasculo-Behçet patients.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2019-10-24
Info
Issue
Section
Case Reports
Keywords:
Behçet’s disease, venous thrombosis, Budd-Chiari, infliximab.
Statistics
  • Abstract views: 636

  • PDF: 386
How to Cite
Santos, L., Rigueira, J., & Vilas, A. (2019). Infliximab in the treatment of Budd-Chiari syndrome in Behçet’s disease. Reumatismo, 71(3), 163-165. https://doi.org/10.4081/reumatismo.2019.1153